


# GETTING THE WORLD VACCINATED AGAINST COVID-19

October 2021 statistics update

## Progress in producing vaccines is much higher than in administering them


In two months (December 2021), global production surpasses the target of 11.3 billion vaccines needed to vaccinate the world. Success in fighting COVID-19 then depends on also distributing and administering these doses globally where industry is supporting as much as possible.

Global vaccine doses produced (billions)



Source: Airfinity (October 2021)

Where are vaccines produced and administered?




Source: Airfinity (October 2021)

Industry has delivered via unparalleled R&D efforts and levels of cooperation, including technology transfers, to develop COVID-19 vaccines and ramp up production sufficient to vaccinate the world by December 2021.

## We have safe and effective COVID-19 vaccines today because of long-term innovation

Developing new vaccine technologies, now mobilised in the fight against COVID-19, have been the result of decades of R&D. Their application to COVID-19 in 2020 was made possible by strong cooperation between industry, regulators and governments.




Source: Airfinity (October 2021)


Innovation and R&D continue to be important to fight new COVID-19 variants of concern and are vital to increase future pandemic preparedness.

## COVID-19 vaccine production is complicated, needs regulatory approval and requires extensive quality control

Number of approved vaccines around the world



Source: McGill COVID19 Vaccine Tracker Team (October 2021)



Source: Vaccines Europe (2021), Airfinity (June 2021), PIIE (2020)

In vaccine production, 70% of the production time is dedicated to quality control and testing. Knowing the ingredients of a vaccine and how to combine them does not mean the expertise and experience are there to successfully produce them.


# GETTING THE WORLD VACCINATED AGAINST COVID-19

October 2021 statistics update


## Trade policy supporting global vaccine exports is a key driver for vaccine equity

Trade protectionism is increasing

COVID-19 vaccine doses produced and exported (Jul/Oct)



Source: Global Trade Alert (24 September 2021)




Source: Airfinity (October 2021)

Trade openness is vital for global supply chains to continue the production of COVID-19 vaccines and to export them, but protectionist measures are not going down. Governments should eliminate trade barriers that impede the distribution of vaccines across borders, for example through the Trade and Health Initiative (TAHI) at the WTO.


## Healthcare system absorptive capacities and vaccine hesitancy are barriers to vaccine equity

Healthcare Access and Quality Index

Willingness to take COVID-19 vaccine (2020, by country, %)



Source: The Lancet (2018)



Source: Gallup (2020), Created with Datawrapper

Healthcare system capacities for COVID-19 vaccine roll-outs vary significantly globally. Especially in Sub-Saharan Africa and South/South-East Asia country readiness needs support.

Vaccine hesitancy varies significantly by country with 96% of Myanmar willing to take a vaccine down to 29% in Gabon and 25% in Kazakhstan according to Gallup (2020).

With production no longer being the bottleneck, high vaccine confidence and healthcare system preparedness for COVID-19 vaccine roll-outs are key factors to get people vaccinated and administer the 12.6 billion doses produced by December 2021.

## Intellectual Property saves lives

IP enables focus on innovation by incentivising long-term R&D

IP facilitates ramping up production through use of best available infrastructure for scaling up

IP facilitates ramping up production through effective collaboration and voluntary technology transfers

IP increases vaccine confidence by reducing the risk of counterfeit vaccines

IP increases global preparedness for new variants of concern and future pandemics

## Five steps to urgently advance COVID-19 vaccine equity



Optimise production



Eliminate trade barriers



Set up dose sharing



Support country readiness



Drive further innovation